Clinical trials: Locally Advanced, open to volunteers
Locally Advanced Gastroesophageal Junction Adenocarcinoma, Chemotherapy Effect
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma
For locally advanced adenocarcinoma of esophagogastric junction(AEG) (cT3-4aN+M0), neoadjuvant chemotherapy was improved to downstage T and N stage, increase the resectability of tumor, and finally improve the long-term survival.
- Trial name
- NCT04989985
- Testing
- Oxaliplatin+S-1, Sinitilimab+oxaliplatin+S-1
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Locally Advanced Gastric Adenocarcinoma
Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
The FOLFIRINOX regimen has become the standard treatment regimen for advanced colorectal cancer, advanced pancreatic cancer and postoperative adjuvant treatment for pancreatic cancer.
- Trial name
- NCT04908566
- Testing
- PD-1 antibody combined with FOLFIRINOX regimen, PD-1 antibody combined with SOX program
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Resectable Locally Advanced Non-small Cell Lung Cancer
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
This is a multicenter, randomized, open label, phase II study.
- Trial name
- ALTER-L043 (NCT04846634)
- Testing
- Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel, Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel, Penpulimab+Anlotinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Non-small Cell Lung Cancer
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
This is a phase II, multicenter, single-arm, non-blind study. To 21 patients with PD-L1 ≥50% locally advanced non-small cell lung cancer, the combination of Pembrolizumab and platinum-doublets will be intravenously administered…
- Trial name
- Evolution (NCT04153734)
- Testing
- Pembrolizumab, Cis Platinum, Carboplatin
- Volunteers
- 21 people
- Sponsor
- Kobe Minimally Invasive Cancer Center
Locally Advanced Gastric Cancer
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer
In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC).
- Trial name
- Neo-D2plus (NCT03961373)
- Testing
- Gastrectomy with D2 lymphadenectomy, Gastrectomy with D2plus lymphadenectomy
- Where
- Italy
- Volunteers
- 539 people
- Sponsor
- University of Siena
LOCALLY ADVANCED RECTAL CANCER
Organ Preservation in Locally Advanced Rectal Cancer
PRONAR trial aims to assess if treatment with organ preservation in stage II and III rectal cancer after a complete or almost complete response to neoadjuvant treatment is feasible and safe in our environment.
- Trial name
- PRONAR (NCT03064646)
- Testing
- Organ Preservation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Locally Advanced Colon Cancer
Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer
Adjuvant chemotherapy has been widely adopted worldwide for locally advanced colon cancer. However, more and more studies have found better efficacy and potential advantages of perioperative or neoadjuvant chemotherapy.
- Trial name
- NCT03125980
- Testing
- capecitabine plus oxaliplatin before and after surgery, capecitabine plus oxaliplatin after surgery
- Where
- China
- Volunteers
- 1,370 people
- Sponsor
- Fudan University